title: Efficacy of taxotere, thalidomide, and prednisolone in patients with hormone-resistant metastatic prostate cancer.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of combination treatment with thalidomide and taxotere in patients with hormone-resistant prostate cancer.
  
  
  METHODS
  This clinical trial was performed on 16 patients with hormone-resistant prostate cancer.
  
  
  RESULTS
  Mean age of the participants was 72.7 ± 5.39 years (range, 65 to 85 years). In 94% of patients who received the drug combination, prostate-specific antigen level decreased more than 50%. The mean time to progression was 15 months and mean survival time was 23 months. This combination therapy had some adverse events.
  
  
  CONCLUSIONS
  Addition of anti-angiogenic agents, such as thalidomide, can improve therapeutic outcome in this group of patients.
authors.affiliation: Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
authors.forename: Hamid
authors.initials: H
authors.lastname: Rezvani
authors.forename: Shirin
authors.initials: S
authors.lastname: Haghighi
authors.forename: Mojtaba
authors.initials: M
authors.lastname: Ghadyani
authors.forename: Hamid
authors.initials: H
authors.lastname: Attarian
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D018572:Disease-Free Survival; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000556:secondary; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D007987:Gonadotropin-Releasing Hormone; D013792:Thalidomide; D011239:Prednisolone; D017430:Prostate-Specific Antigen